This National Cancer Institute grant supports the Pancreatic Cancer Detection Consortium (PCDC) Research Units (RUs) to advance early detection of pancreatic ductal adenocarcinoma (PDAC) and characterize precursor lesions. The PCDC-RUs will conduct multidisciplinary research, developing and testing new molecular and imaging biomarkers for early PDAC and identifying high-risk patients. Studies include identifying fluid-based biomarkers, determining cyst progression, developing high-risk population screening approaches, utilizing machine learning for biomarker discovery, and conducting validation studies. PCDC-RUs will also collect longitudinal biospecimens for a biorepository and collaborate extensively within the Consortium to share ideas, biospecimens, and data.
Opportunity ID: 335737
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-335 |
| Funding Opportunity Title: | Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 16, 2021 |
| Last Updated Date: | Sep 16, 2021 |
| Original Closing Date for Applications: | Jun 11, 2024 |
| Current Closing Date for Applications: | Jun 11, 2024 |
| Archive Date: | Jul 17, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Independent school districts Public housing authorities/Indian housing authorities County governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments For profit organizations other than small businesses Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute’s 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-335.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 335737 Full Announcement-PAR-21-335 -> PAR-21-335-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269603 | Oct 27, 2021 | Jan 24, 2023 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268963 | Oct 15, 2021 | Jan 24, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277599 | Oct 31, 2022 | Jun 11, 2024 | View |
Package 1
Mandatory forms
335737 RR_SF424_5_0-5.0.pdf
335737 PHS398_CoverPageSupplement_5_0-5.0.pdf
335737 RR_OtherProjectInfo_1_4-1.4.pdf
335737 PerformanceSite_4_0-4.0.pdf
335737 RR_KeyPersonExpanded_4_0-4.0.pdf
335737 RR_Budget_3_0-3.0.pdf
335737 PHS398_ResearchPlan_4_0-4.0.pdf
335737 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335737 RR_SubawardBudget30_3_0-3.0.pdf
335737 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
335737 RR_SF424_2_0-2.0.pdf
335737 PHS398_CoverPageSupplement_5_0-5.0.pdf
335737 RR_OtherProjectInfo_1_4-1.4.pdf
335737 PerformanceSite_2_0-2.0.pdf
335737 RR_KeyPersonExpanded_2_0-2.0.pdf
335737 RR_Budget_1_4-1.4.pdf
335737 PHS398_ResearchPlan_4_0-4.0.pdf
335737 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335737 RR_SubawardBudget30_1_4-1.4.pdf
335737 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
335737 RR_SF424_5_0-5.0.pdf
335737 PHS398_CoverPageSupplement_5_0-5.0.pdf
335737 RR_OtherProjectInfo_1_4-1.4.pdf
335737 PerformanceSite_4_0-4.0.pdf
335737 RR_KeyPersonExpanded_4_0-4.0.pdf
335737 RR_Budget_3_0-3.0.pdf
335737 PHS398_ResearchPlan_5_0-5.0.pdf
335737 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
335737 RR_SubawardBudget30_3_0-3.0.pdf
335737 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
